Business Context and Reporting Period
This Form 8-K Current Report was filed by AngioDynamics, Inc. on July 27, 2016. The filing addresses corporate governance changes under Item 5.02 regarding the appointment of certain officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and contains no financial performance data.
Material Changes
The primary material change reported is the appointment of Peter J. Kish as the Company's Principal Financial Officer and Principal Accounting Officer, effective July 27, 2016. This appointment is interim, serving until Michael Greiner assumes the role of Chief Financial Officer on August 16, 2016.
Management Commentary and Risks
Management Commentary: Mr. Kish, age 61, has served as a consultant to the Company since May 16, 2016. He is currently a CFO Engagement Partner with Tatum, a Randstad Company. His background includes 15 years at Kulicke & Soffa Industries, Inc., where he served as Vice President and Corporate Controller, as well as management roles at Bristol Myers Squibb and MacMillan Publishing.
Risks and Contingencies: The filing states that Mr. Kish has no family relationship with the Company's directors or executive officers and is not a party to any transactions listed in Item 404(a) of Regulation S-K. No other risks or contingencies are disclosed in this specific filing.
Investor Verification Checklist
- Verify the start date of Michael Greiner's tenure as Chief Financial Officer (August 16, 2016).
- Confirm the interim nature of Peter J. Kish's role as Principal Financial Officer.
- Review subsequent filings for the official transition of financial leadership duties.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.